Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 4/20 | 0.35 |
| ▸ | CYP4A11 | Q02928 | 4/20 | 0.35 |
| ▸ | SLC16A3 | O15427 | 3/20 | 0.34 |
| ▸ | SLC16A1 | P53985 | 3/20 | 0.34 |
| ▸ | MCTS1 | Q9ULC4 | 2/20 | 0.34 |
| ▸ | SMYD2 | Q9NRG4 | 2/20 | 0.33 |
| ▸ | ATR | Q13535 | 3/20 | 0.32 |
| ▸ | RXRA | P19793 | 1/20 | 0.32 |
| ▸ | RXRB | P28702 | 1/20 | 0.32 |
| ▸ | RXRG | P48443 | 1/20 | 0.32 |
| ▸ | GRM5 | P41594 | 3/20 | 0.31 |
| ▸ | CFTR | P13569 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22825574 | 0.83 | CYP4F2 (0.36) | CYP4F2CYP4A11SLC16A3SLC16A1MCTS1 | |
| SCHEMBL24977875 | 0.78 | CYP4F2 (0.36) | CYP4F2CYP4A11SLC16A3SLC16A1MCTS1 | |
| SCHEMBL19469221 | 0.76 | SMYD2 (0.33) | SLC16A3SLC16A1MCTS1SMYD2 | |
| SCHEMBL15633152 | 0.76 | GRM5 (0.34) | CYP4F2CYP4A11SLC16A3SLC16A1MCTS1 | |
| SCHEMBL24977637 | 0.71 | TDP1 (0.38) | CYP4F2CYP4A11 | |
| SCHEMBL22826015 | 0.69 | CYP4F2 (0.39) | CYP4F2CYP4A11SLC16A3SLC16A1MCTS1 | |
| SCHEMBL22412880 | 0.67 | MEN1 (0.39) | SLC16A3SLC16A1MCTS1SMYD2 | |
| SCHEMBL20390489 | 0.67 | CYP4F2 (0.35) | CYP4F2CYP4A11ATR | |
| SCHEMBL3338672 | 0.67 | RXRA (0.35) | CYP4F2CYP4A11ATRRXRARXRB | |
| SCHEMBL176777 | 0.67 | DGAT2 (0.37) | CYP4F2CYP4A11ATRRXRARXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230021562-A1 | MACROCYLIC INDOLE DERIVATIVES MCL-1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230021562-A1 | MACROCYLIC INDOLE DERIVATIVES MCL-1 INHIBITORS | MCL1, BCL2L1, BAK1 | CYP4F2 4722/4885CYP4A11 4575/4885SLC16A3 3924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.